AR132786A1 - Receptores de conmutación - Google Patents

Receptores de conmutación

Info

Publication number
AR132786A1
AR132786A1 ARP240101333A ARP240101333A AR132786A1 AR 132786 A1 AR132786 A1 AR 132786A1 AR P240101333 A ARP240101333 A AR P240101333A AR P240101333 A ARP240101333 A AR P240101333A AR 132786 A1 AR132786 A1 AR 132786A1
Authority
AR
Argentina
Prior art keywords
nucleic acid
cell
nucleic acids
receptor polypeptide
chimeric receptor
Prior art date
Application number
ARP240101333A
Other languages
English (en)
Inventor
Stephan Gasser
Christian Klein
Dominic Schwarz
Dario Venetz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR132786A1 publication Critical patent/AR132786A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/24—Dimerizable CARs; CARs with adapter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere a los campos de la biología molecular, más específicamente, receptores de citocina. La presente divulgación también se refiere a métodos de tratamiento médico y profilaxis, en particular, inmunoterapia celular. Reivindicación 1: Un polipéptido del receptor quimérico que comprende: (i) una porción extracelular que comprende un dominio de unión a IL23; (ii) una porción intracelular que comprende los dominios intracelulares de IL12Rb2 (receptor b 2 de interleucina-12); y (iii) un dominio transmembrana que une la porción extracelular y la porción intracelular. Reivindicación 22: Un ácido nucleico, o una pluralidad de ácidos nucleicos, que codifican un polipéptido del receptor quimérico de acuerdo con cualquiera de las reivindicaciones 1 - 21, y que opcionalmente comprende además una secuencia de ácidos nucleicos que codifica un receptor de antígeno quimérico. Reivindicación 23: Un vector de expresión, o una pluralidad de vectores de expresión, que comprenden un ácido nucleico, o una pluralidad de ácidos nucleicos, de acuerdo con la reivindicación 22. Reivindicación 24: Una célula que comprende un polipéptido del receptor quimérico de acuerdo con cualquiera de las reivindicaciones 1 - 21, un ácido nucleico o una pluralidad de ácidos nucleicos de acuerdo con la reivindicación 22, o un vector de expresión o una pluralidad de vectores de expresión de acuerdo con la reivindicación 23. Reivindicación 49: Una composición farmacéutica que comprende la célula de acuerdo con cualquiera de las reivindicaciones 24 - 36 y opcionalmente un excipiente farmacéuticamente aceptable. Reivindicación 50: Un polipéptido del receptor quimérico de acuerdo con las reivindicaciones 1 - 21, o un ácido nucleico de acuerdo con la reivindicación 22, o un vector de acuerdo con la reivindicación 22, o una célula de acuerdo con cualquiera de las reivindicaciones 34 - 36, o una composición farmacéutica de acuerdo con la reivindicación 49, para su uso en un método de tratamiento médico de una enfermedad o profilaxis de una enfermedad. Reivindicación 55: Un método para modular la actividad de una célula inmunitaria, en donde dicho método comprende: administrar, a una célula inmunitaria, el ácido nucleico o pluralidad de ácidos nucleicos de acuerdo con la reivindicación 22, o el vector de expresión o pluralidad de vectores de expresión de acuerdo con la reivindicación 23.
ARP240101333A 2023-06-06 2024-05-27 Receptores de conmutación AR132786A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP23177793 2023-06-06

Publications (1)

Publication Number Publication Date
AR132786A1 true AR132786A1 (es) 2025-07-30

Family

ID=86731992

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101333A AR132786A1 (es) 2023-06-06 2024-05-27 Receptores de conmutación

Country Status (14)

Country Link
EP (1) EP4724086A1 (es)
JP (1) JP2026524081A (es)
KR (1) KR20260020404A (es)
CN (1) CN121240874A (es)
AR (1) AR132786A1 (es)
AU (1) AU2024286646A1 (es)
CL (1) CL2025003759A1 (es)
CO (1) CO2025016585A2 (es)
CR (1) CR20250523A (es)
IL (1) IL324488A (es)
MX (1) MX2025014670A (es)
PE (1) PE20260557A1 (es)
TW (1) TW202506711A (es)
WO (1) WO2024251547A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056837A1 (en) 2017-03-27 2018-10-04 F. Hoffmann-La Roche Ag Improved antigen binding receptors
BR112022003553A2 (pt) * 2019-08-30 2022-05-24 Allogene Therapeutics Inc Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta
WO2022029051A1 (en) 2020-08-03 2022-02-10 F. Hoffmann-La Roche Ag Improved antigen binding receptors
WO2022032042A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Il12 receptor synthetic cytokines and methods of use
WO2023081813A1 (en) * 2021-11-05 2023-05-11 St. Jude Children's Research Hospital, Inc. Zip cytokine receptors

Also Published As

Publication number Publication date
AU2024286646A9 (en) 2025-12-11
KR20260020404A (ko) 2026-02-11
CR20250523A (es) 2026-01-14
TW202506711A (zh) 2025-02-16
IL324488A (en) 2026-01-01
CO2025016585A2 (es) 2025-12-09
EP4724086A1 (en) 2026-04-15
CL2025003759A1 (es) 2026-01-09
AU2024286646A1 (en) 2025-11-27
JP2026524081A (ja) 2026-07-17
MX2025014670A (es) 2026-01-07
CN121240874A (zh) 2025-12-30
WO2024251547A1 (en) 2024-12-12
PE20260557A1 (es) 2026-03-04

Similar Documents

Publication Publication Date Title
RU2012149858A (ru) Получение гетеромультимерных белков
Düesberg et al. Cell activation by synthetic lipopeptides of the hepatitis C virus (HCV)—Core protein is mediated by toll like receptors (TLRs) 2 and 4
ES2290241T3 (es) Anticuerpos monoclonales contra el receptor de interferon, con actividad neutralizadora contra el interferon de tipo i.
Hughes Jr et al. LPS stimulated invertebrate hemocytes: a role for immunoreactive TNF and IL-1
Samara et al. Prothymosin alpha and immune responses: are we close to potential clinical applications?
UA55371C2 (uk) Олігопептид, який розпізнається та протеолітично розщеплюється вільним простатичним антигеном, спосіб визначення протеолітичної активності вказаного антигену, спосіб ідентифікації сполук, які інгібують протеолітичну активність вказаного антигену, кон'югат, який використовують для лікування раку передміхурової залози
CN109652379A (zh) Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用
CN109069635A (zh) 人源化抗cd3抗体、偶联物及其用途
EA036386B1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
ES2112838T3 (es) Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas.
MX2022008654A (es) Formulaciones para productos terapeuticos proteicos.
Rudra et al. Immune responses to coiled coil supramolecular biomaterials
MX2023010939A (es) Metodos y composiciones de muteinas de il2 sesgadas.
Gregory et al. Luteinizing hormone release from dissociated pituitary cells by dimerization of occupied LHRH receptors
CA2177179C (en) Antagonists to chaperonin 10
Karaöz et al. Reduction of lesion in injured rat spinal cord and partial functional recovery of motility after bone marrow derived mesenchymal stem cell transplantation
SASAKI et al. Secretion of transforming growth factor-β1 and-β2 by malignant glioma cells
CL2024003622A1 (es) Proteína de unión a antígeno tigit; método de producción; composición farmacéutica; y su uso.
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos
UA52646C2 (uk) Гібридні білки, фармацевтична композиція, що містить гібридний білок, ізольована молекула днк, що містить гібридний білок, вектор експресії, клітина-хазяїн, спосіб продукування гібридного білка, спосіб індукування визрівання фолікулів
ES2144418T3 (es) Peptidos de receptores de celulas t como agentes terapeuticos para enfermedades relacionadas con el sistema inmunitario.
JP2024539281A5 (es)
BR112023019385A2 (pt) Composições compreendendo polipeptídeos de fusão nkg2d, cxcr2 e dap10/dap12 e seus métodos de uso
Shen et al. Killer artificial antigen-presenting cells deplete alloantigen-specific T cells in a murine model of alloskin transplantation
US20250257332A1 (en) Truncated and fusion proteins